OpenAI Launches GPT-Rosalind, a Restricted Biology Model for Drug Discovery
OpenAI released GPT-Rosalind, a frontier reasoning model built specifically for biology and drug discovery — but access is limited to vetted research partners, signaling a new era of gated domain-specific AI.
OpenAI quietly dropped GPT-Rosalind this week, a domain-specific model designed for drug discovery, genomics, and life sciences research. As @minchoi reported, the model represents OpenAI's deepest push yet into specialized scientific AI. @AILeaksAndNews added that the model is explicitly described as a frontier AI reasoning system "built to support research across biology, drug discovery, and the life sciences."
Unlock the full briefing
Get every story in today's briefing, the full archive, and the daily AI intelligence brief.
All stories today
Full archive
Daily brief
Cancel anytime. Payments powered by Stripe.